Wirestock
- GSK (GSK) said the U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 and older.
- The FDA approval of Exdensur is based on data from the SWIFT-1 and
